Crinetics Pharmaceuticals (CRNX)
(Delayed Data from NSDQ)
$42.29 USD
-1.03 (-2.38%)
Updated Apr 25, 2024 04:00 PM ET
After-Market: $42.30 +0.01 (0.02%) 5:48 PM ET
3-Hold of 5 3
F Value F Growth C Momentum F VGM
Crinetics Pharmaceuticals, Inc. (CRNX) Price Targets
Average Price Target | Highest Price Target | Lowest Price Target | Upside to Average Price Target |
---|---|---|---|
$56.54 | $80.00 | $40.00 | 30.52% |
Price Target
Based on short-term price targets offered by 13 analysts, the average price target for Crinetics Pharmaceuticals, Inc. comes to $56.54. The forecasts range from a low of $40.00 to a high of $80.00. The average price target represents an increase of 30.52% from the last closing price of $43.32.
Analyst Price Targets (13)
Broker Rating
Crinetics Pharmaceuticals, Inc. currently has an average brokerage recommendation (ABR) of 1.15 on a scale of 1 to 5 (Strong Buy to Strong Sell), calculated based on the actual recommendations (Buy, Hold, Sell etc.) made by 13 brokerage firms. The current ABR compares to an ABR of 1.15 a month ago based on 13 recommendations.
Of the 13 recommendations deriving the current ABR, 12 are Strong Buy, representing 92.31% of all recommendations. A month ago, Strong Buy represented 92.31%.
Broker Rating Breakdown
Brokerage Recommendations
Today | 1 Week Ago | 1 Month Ago | 2 Months Ago | 3 Months Ago | |
---|---|---|---|---|---|
Strong Buy | 12 | 12 | 12 | 11 | 11 |
Buy | 0 | 0 | 0 | 0 | 0 |
Hold | 1 | 1 | 1 | 1 | 1 |
Sell | 0 | 0 | 0 | 0 | 0 |
Strong Sell | 0 | 0 | 0 | 0 | 0 |
ABR | 1.15 | 1.15 | 1.15 | 1.17 | 1.17 |
1. Not Ident. Many of the brokerage firms who provide Zacks data ask that we keep their identity confidential.
2. In most cases the # of brokers listed above is less than the # of brokerage firms that have a recommendation on the stock. That is because some firms prohibit Zacks from displaying detailed information on their recommendations such as in the upgrade/downgrade table.
Analyst Upgrades/Downgrades
Date | Brokerage Firm | Analyst | Previous | Current |
---|---|---|---|---|
3/8/2024 | H.C. Wainwright & Co. | Douglas Tsao | Strong Buy | Strong Buy |
3/4/2024 | Cantor Fitzgerald & Co | Josh Schimmer | Strong Buy | Strong Buy |
2/29/2024 | Robert W. Baird & Co. | Brian P Skorney | Strong Buy | Strong Buy |
2/29/2024 | JMP Securities | Jonathan Wolleben | Strong Buy | Strong Buy |
2/1/2024 | Piper Sandler | Yasmeen Rahimi | Strong Buy | Strong Buy |
11/8/2023 | LifeSci Capital | Cory Jubinville | Strong Buy | Strong Buy |
11/7/2023 | SVB Securities | Joseph P Schwartz | Strong Buy | Strong Buy |
9/11/2023 | Evercore Partners | Gavin Clark-Gartner | Not Available | Strong Buy |
1. Not Ident. Many of the brokerage firms who provide Zacks data ask that we keep their identity confidential.
2. In most cases the # of brokers listed above is less than the # of brokerage firms that have a recommendation on the stock. That is because some firms prohibit Zacks from displaying detailed information on their recommendations such as in the upgrade/downgrade table.
Average Brokerage Rating
Current ABR | 1.15 |
ABR (Last week) | 1.15 |
# of Recs in ABR | 13 |
Average Target Price | $56.54 |
LT Growth Rate | NA |
Industry | Medical - Drugs |
Industry Rank by ABR | 93 of 252 |
Current Quarter EPS Est: | -0.84 |